The ability to generate region-specific three-dimensional (3D) models to study human brain development offers great promise for understanding the nervous system in both healthy individuals and patients. In this protocol, we describe how to generate and assemble subdomain-specific forebrain spheroids, also known as brain region-specific organoids, from human pluripotent stem cells (hPSCs). We describe how to pattern the neural spheroids toward either a dorsal forebrain or a ventral forebrain fate, establishing human cortical spheroids (hCSs) and human subpallial spheroids (hSSs), respectively. We also describe how to combine the neural spheroids in vitro to assemble forebrain assembloids that recapitulate the interactions of glutamatergic and GABAergic neurons seen in vivo. Astrocytes are also present in the human forebrain-specific spheroids, and these undergo maturation when the forebrain spheroids are cultured long term. The initial generation of neural spheroids from hPSCs occurs in <1 week, with regional patterning occurring over the subsequent 5 weeks. After the maturation stage, brain region-specific spheroids are amenable to a variety of assays, including live-cell imaging, calcium dynamics, electrophysiology, cell purification, single-cell transcriptomics, and immunohistochemistry studies. Once generated, forebrain spheroids can also be matured for >24 months in culture.
Introduction
Understanding the development of the human nervous system and elucidating the mechanisms that lead to brain disorders represent some of the most challenging ongoing endeavors in neurobiology. One major obstacle is the restricted access to healthy and diseased human brain tissue for functional molecular and cellular studies 1, 2 . As a result, experimental paradigms have been largely confined to animal models or in vitro cell culture systems that do not fully recapitulate the developmental, architectural, and species-specific aspects of the human brain. Thus, there is a great need for humanderived model systems that recapitulate features of human CNS development and allow for the study of these processes in both healthy and diseased conditions.
Modeling human neural development with pluripotent stem cells
The ability to reprogram human somatic cells to induced pluripotent stem cells (hiPSCs) [3] [4] [5] and subsequently differentiate these cells into neural lineages provides the opportunity to study features of human neural development in vitro 6 . In addition, these systems allow scientists to link rare, highly penetrant mutations, as well as more complex genetic events, to cellular disease phenotypes 7, 8 . Initial patient-derived hiPSC models are centered on the use of adherent two-dimensional (2D) cell culture systems [9] [10] [11] [12] [13] . These protocols generate relatively homogeneous populations of neural types but do not capture the cellular diversity or 3D tissue architecture 14 . 3D human brain cultures were established to provide physiologically relevant models that more faithfully recapitulate the spatial organization, cellular diversity, and cell-cell interactions that are present in the developing human nervous system 15, 16 . In this protocol, we describe how to generate brain region-specific spheroids from hiPSCs or human embryonic stem cells (hESCs). These region-specific spheroids or organoids are patterned to resemble the dorsal forebrain, also known as the pallium (hCSs) 17, 18 , or the ventral forebrain, also known as the subpallium (hSSs) 19 . The protocol consists of neural induction of 3D aggregates of hPSCs, followed by culture in the presence of a variety of small molecules to derive specific cell fates. We have previously used this protocol for the in vitro study of the development of the human cerebral cortex 17 and the maturation of glial cells into postnatal stages 20 neural cells of novel adeno-associated virus (AAV) subtypes 21 , to model interregional cross-talk in the developing forebrain, and to identify phenotypes in a monogenic form of autism spectrum disorders 19 . Because neural spheroids are derived from reprogrammed human cells, they are an ideal system for studying disease phenotypes from specific human genetic backgrounds 18 . In addition, this platform allows for the study of later stages of human brain development, including the maturation of astrocytes 20 , and can be used to derive and assemble different region-specific spheroids into 'brain assembloids', which can be used to study cell migration and neural circuit formation 19 .
Features of human forebrain development
Human forebrain development proceeds through a series of stereotyped steps that are guided by specific patterning cues 22, 23 . Early in embryonic development, the neural tube begins to expand and forms three primary pouches, which are anatomic structures that will eventually segregate into the forebrain (prosencephalon), midbrain (mesencephalon), and hindbrain (rhombencephalon) 24 . The maturing forebrain can be anatomically and functionally subdivided along a dorsal-ventral axis, with the dorsal region (pallium) eventually generating the bulk of the cerebral cortex and the ventral region (subpallium) comprising the lateral and medial/caudal divisions of the ganglionic eminences (LGE and MGE/CGE, respectively) 25 . These eminences are the origin of cortical interneuron populations 26 . The vast majority of GABAergic interneurons are born in the MGE or the CGE, where they also acquire specific subtype identities (e.g., parvalbumin, somatostatin, and calbindin). Having been specified in the subpallium, these interneurons begin a migratory journey to populate the developing dorsal pallium. Around gestational week (GW) 15 in humans, interneurons exit the pallial-subpallial border and enter the dorsal forebrain via tangential migration to disperse throughout the subplate, cortical plate, and marginal zones 27 . This process continues in frontal cortical regions from then onward and throughout the second year of life in humans 28 . These cortical interneurons then undergo an activity-dependent maturation process and integrate into neural circuits 29 , where they contribute to the excitation-to-inhibition balance (E/I). This is a critical process in CNS development and circuit functioning. Furthermore, genetic or environmental imbalances of the E/I are thought to contribute to neuropsychiatric disorders such as epilepsy, autism spectrum disorders, and intellectual disabilities 30, 31 . Neuronal production is just one of the many components of CNS development. During later gestational stages and continuing after birth in humans, neural progenitors switch from a largely neurogenic to a gliogenic fate, generating astrocytes and later oligodendrocytes 32, 33 . This transition constitutes the bulk of astrogenesis, as newly born astrocyte precursor cells begin to populate the brain parenchyma and distribute throughout the CNS in a tiled distribution. Astrocytes help choreograph neural development and actively contribute to neural circuit formation by controlling synapse formation, function, and elimination. This raises the possibility that astrocyte dysfunction may also directly contribute to the pathophysiology of neuropsychiatric disorders.
Development of the method and comparison with other approaches
In recent years, a number of 3D brain tissue models have been developed 16, 17, [34] [35] [36] [37] , each with specific advantages and disadvantages. What is common among these methodologies is that they use the capacity of hPSCs to differentiate and self-organize in a 3D environment and to recapitulate key features of human brain development, such as the presence of ventricular-like structures surrounded by progenitor populations that differentiate into multiple cell lineages.
The method we describe here builds upon several previous advances. Inhibitors of the SMAD pathway were shown to induce rapid and fast neural differentiation of high-density hPSCs with a default dorsal forebrain fate 38 . In addition, hPSCs were shown to undergo neural differentiation following aggregation in the presence of a ROCK inhibitor in V-or U-shaped wells, followed by plating in 2D cultures several weeks later 39 . Building upon these studies, we developed an approach that involves transferring intact colonies of hPSCs to ultra-low-attachment plates and culturing these cells exclusively in suspension without an extracellular matrix or a bioreactor, in the presence of two inhibitors of the SMAD pathway to facilitate neuralization 17 . For neuralization, we have primarily used dorsomorphin (DM) and SB-4321542 (SB), but other combinations of SMAD inhibitors can be used. Our approach also uses a longer exposure to the growth factors EGF and FGF2 to allow proliferation and corticogenesis progression, followed by an 18-d exposure to BDNF and NT3 for maturation. This protocol yields self-organizing 3D cultures resembling the dorsal forebrain, which can be maintained for years, displaying cellular features observed in the postnatal brain 20 . We have subsequently developed a complementary approach to derive ventral forebrain 3D cultures in which dual SMAD inhibition is followed by exposure to a small-molecule sonic hedgehog agonist, retinoic acid (RA), for fate specification, and allopregnanolone (AlloP), for neural maturation 19 . Overall, our method yields region-specific 3D forebrain cultures. In the years following the development of the protocol outlined here, a number of additional groups have continued to adapt the strategy of regional patterning to obtain other brain region-specific patterned structures, such as midbrain, hindbrain, or cerebellum 17, [35] [36] [37] 40 . In addition, and in contrast, other groups have combined the intrinsic differentiation ability and the inherent self-differentiation cues within hPSCs with extracellular matrices or bioreactors to develop organoids via an undirected approach 34 . Without specific inductive signals, this approach has the advantage of generating a variety of cell fates within and across organoids. Single-cell transcriptomic studies of undirected organoids 41 confirm the presence of mixed dorsal and ventral forebrain cell lineages, along with cells from other brain regions, such as hindbrain, midbrain, retina, and mesodermal cells. This high degree of cellular diversity may allow for future studies of human CNS diversity and mapping of genes associated with neuropsychiatric disease onto specific cell types 16 . However, given the lack of external cues, these undirected differentiation techniques tend to display a higher degree of stochasticity and may exhibit a degree of variation in cell types and maturation that can make interpreting disease phenotypes challenging.
One application of the region-specific brain spheroids is for modeling interregional interactions in CNS development 19 . In this modular approach, separately patterned ventral and dorsal forebrain spheroids are cultured together so that they fuse and generate forebrain assembloids. This enables cortical GABAergic neurons, which are specified in ventral forebrain spheroids, to migrate toward the dorsal forebrain spheroid and then to synaptically integrate into networks with cortical glutamatergic neurons. This platform allows live monitoring and genetic and pharmacological manipulation of cortical interneuron migration, a process that happens at the late stages of human gestation. Importantly, we have compared our findings with results from human primary fetal forebrain slices (GW 20) . We have also demonstrated the power of this platform to identify cell-specific phenotypes and rescue strategies by deriving forebrain assembloids from patients with a rare genetic form of autism spectrum disorder and epilepsy 19 . Two other groups have subsequently adapted similar, assembly-based approaches to re-create and modulate cell migration from ventral forebrain (subpallium)-like to dorsal forebrain (pallium)-like 3D cultures 42, 43 . Bagley et al. 42 used Matrigelembedding and an orbital shaker for assembly, whereas Xiang et al. 43 implemented a spontaneous fusion approach. Each study also used a unique molecular-labeling approach to track migrating cells from one 3D culture to the other. For example, Bagley et al. used an EF1α-GFP-expressing hPSC line to track the population of migrating cells (60% of which were GABAergic cells), whereas Xiang et al. used an NKX2.1-GFP hPSC line (similar to the Dlxi1/2b::GFP enhancer we have used) to track MGE-lineage cells. These studies show that brain assembloids can reproducibly model interregional interactions and complex cellular phenotypes such as cell migration in a 3D microphysiological environment.
Applications and limitations
hPSC-derived 3D cultures can be used to address questions that are related to human brain development and disease modeling 15, 44 . One particular advantage of this method is the ability to investigate human-specific phenotypes in patient-derived cultures, which may be challenging to capture in other systems. The entirety of the protocol described here is performed in ultra-low-attachment culture plates without embedding into extracellular matrices or the use of spinning bioreactors. At later stages of differentiation, cell death may be observed in hCSs and hSSs. However, our biosensor measurements demonstrate a partial pressure of oxygen that remains >60 mmHg in the center of hCSs that are 4 mm in diameter.
The brain region-specific spheroids we obtain are amenable to many downstream assays and analyses (Fig. 1) . They can be fixed and cryosectioned for immunohistochemistry ( Step 23C) or in situ hybridization, and they can be used intact for live-cell imaging using a variety of microscopy setups (e.g., Step 23D, F). In addition, they can be easily dissociated for sorting into distinct cell populations (Step 23B), immunopanning, or single-cell transcriptomics. Forebrain spheroids resembling the dorsal or ventral part can also be fused to form assembloids 19, 42, 43 ( Step 23A). This system captures the interactions of various region-specific neuronal and/or glial populations, including the migration and integration of GABAergic neurons into the cerebral cortex. Forebrain spheroids can be cryosectioned for immunostaining ( Step 23C) and are amenable to physiology experiments in slices. They can also be loaded with calcium-sensitive dyes for probing neuronal activity (see ref. 19 for detailed protocols). Neural spheroids can be easily transfected at any stage with viruses carrying a variety of constructs (Box 1) and can even be transplanted with exogenous cell types such as microglia or oligodendrocytes, which engraft and migrate into the parenchyma of the 3D structure.
The system is easily scalable and therefore can be used for toxicology, CRISPR/Cas9 genome editing, and drug-screening paradigms. In addition, although the protocol described here includes growing hPSCs on MEFs, optimization to feeder-free and xeno-free conditions is currently in process and should be achievable. Perhaps most importantly, forebrain spheroids can be maintained in suspension culture for long periods of time 20 (>25 months, in our experience), which allows for the study of cell diversity and maturation as the spheroids age in vitro.
Nevertheless, although there has been unprecedented progress in the ability to differentiate hPSCs into cell types of interest and rapid advances in the ability to grow cells in 3D cultures, there are still substantial issues that must be addressed. These include the need to promote further functional maturation of neurons and glial cells, which could require more physiological medium formulations, improved extracellular matrices, or novel strategies for perfusion and grafting into mammalian tissue 16 . In addition, to capture the regional diversity of the human CNS, additional protocols will need to be developed for deriving and assembling other nervous system regions, such as the thalamus, brainstem, or spinal cord. To capture the cellular diversity and study complex cell-cell interactions in the CNS, future organoid or assembloid models could incorporate myelinating oligodendrocytes, microglia, and vascular cell types. Variability between organoids is a barrier to disease modeling, and thus tools for controlling their internal organization, such as the use of organizer-like molecules (e.g., morphogens soaked in beads), could become powerful strategies. Developing strategies for accelerating the maturation and senescence of human neural cells will be critical to developing in vitro models of neurodegenerative disorders. Last, there is a need to be able to scale up culture systems to facilitate the running of large drug and genetic screens or studies across large cohorts of patients and controls. Over the next few years, as the field evolves, this technology promises to accelerate the study of human brain development, evolution, and disease.
Experimental design
Before beginning experiments, it is important to consider several key points that will help determine the scale and time required to perform adequately powered differentiation experiments:
• All experiments should be performed using at least three hPSC lines, with at least three separate differentiations, and using at least two to three neural spheroids per differentiation or condition.
• If validating disease phenotypes, the use of isogenic hPSC lines is essential.
• The results from hESC and hiPSC experiments should be reported separately. We have successfully generated neural spheroids from >70 hiPSC lines and hESCs such as H9.
• Some line-to-line heterogeneity (especially in early stages of differentiation) can be expected, but there should be consistency within lines and across separate differentiations of the same line.
• For intra-spheroid quantifications, at least three to five sections per spheroid should be used.
In addition, it is important to undertake the following quality-control steps during the differentiation and patterning process: • Cultures of hPSCs, hCSs, and hSSs must be regularly checked for mycoplasma (one to two times/ month).
• Genome integrity of hPSCs must be verified regularly by SNP array or comparative genomic hybridization arrays to identify de novo genomic events. If any abnormalities are noted, earlier passages of cells should be used. For differentiations, we primarily use hPSC lines between passages 10 and 40.
• The quality (size, shape, tendency to differentiate) of hPCSs must be checked daily before starting a new differentiation experiment. It is important to ensure that the properties of hPSCs are consistent across passages and before differentiations.
• Cultures should be checked regularly for bacterial/fungal infection. If the medium is found to be cloudy, it should be checked under the microscope at 40× magnification to identify moving bacteria or fungi. It is important to determine the type of contamination immediately and take appropriate measures.
• From days 0 to 6 of differentiation, newly formed neural spheroids must be checked daily for disintegrating/dying cells (the medium will be cloudy at the bottom of the plate and many floating single cells may be observed under the microscope). If cell death or spheroid disintegration exceeds expectations, it is likely that the differentiation will not progress, and it is better to discard the plates.
• The health of spheroids may vary over the culture period and be dependent on the quality of the founder hPSC colonies. Consider sampling hCSs or hSSs and carrying out periodic immunostaining to assess health. Generally, autofluorescence in the center of sectioned spheroids or detaching cells on the surface indicates cell death.
• Consider introducing quality controls for differentiation efficiency by running quantitative PCRs (qPCRs) for a panel of fate-and region-specific genes at particular time points during the differentiation (e.g., day 25).
Overview of the procedure
The procedure starts with culture and passage of hPSCs on a MEF feeder layer (Steps 1-13) (Fig. 2) . When hPSC colonies reach around 1.5 mm in diameter, they are suspended in medium (Steps 14-16) and cultured in specific culture conditions that induce neuronal differentiation (Steps 17-21).
Step 22 describes the specific culture conditions required to differentiate neural spheroids into hSSs or hCSs. In
Step 23 of the procedure, we describe how to carry out various downstream assays. We also describe how to virally label hCSs and hSSs, which can be carried out at any stage of spheroid growth, in Box 1. Representative image of ideal hPSC colonies either before passaging or enzymatic lifting to form spheroids. Scale bar, 600 μm. b, Details of how to lift hPSC colonies to form spheroids using the enzyme dispase. Representative image of colonies immediately after dispase treatment. Scale bar, 150 μm. c, Neural induction and patterning protocols, and the timeline for the generation of dorsal and ventral forebrain-specific 3D cultures, including hSS-ISRA (option C, which includes exposure to RA and AlloP). D, day. The results shown here are from experiments using hPSCs that conformed to institutional and federal regulations. IRB panel approval and appropriate informed consent were obtained for these studies.
Materials
Biological materials
• Human pluripotent stem cells (hPSCs); forebrain spheroids can be generated from cultures of either hESCs, e.g., H9, or hiPSCs. ! CAUTION The experiments involving hPSCs in this study were approved by the Stanford University School of Medicine Institutional Review Board (IRB) and Stem Cell Research Oversight. The hPSCs used to generate the results shown in this protocol were derived at Stanford University and validated using standardized methods (e.g., pluripotency assays, genomeintegrity checks), as previously described 10, 45, 46 . Cultures were tested and maintained mycoplasmafree. All experiments involving the use of hPSCs must conform to institutional and federal regulations, including IRB panel approval and appropriate informed consent.
• EmbryoMax primary mouse embryo fibroblasts, neo resistant, Myto-C treated (Millipore, cat. no.
PMEF-N-K); alternatively, DR4 mouse embryo fibroblasts (Stanford Human Pluripotent Stem Cells Core Facility) can also be used.
Reagents

Media and supplements
• DMEM (Life Technologies, cat. no. 10313-039)
• DMEM/F12 (1:1; Life Technologies, cat. no. 11330-032)
• Neurobasal A medium (Life Technologies, cat. no. 10888022) ! CAUTION Neurobasal A medium is extremely sensitive to changes in temperature and light. Keep refrigerated at all times.
• FBS albumin, certified (Life Technologies, cat. no. 16000-044) c CRITICAL To avoid lot-to-lot variability biases, we recommend testing and purchasing this product in bulk.
• KnockOut serum replacement (KSR; Life Technologies, cat. no. 10828-028) c CRITICAL To avoid lot-to-lot variability biases, we recommend testing and purchasing this product in bulk.
• B27 supplement (Life Technologies, cat. no. 12587010) c CRITICAL Use B27 supplement without vitamin A. To avoid lot-to-lot variability biases, we recommend testing and purchasing this product in bulk. Procedure 1 hCSs and/or hSSs can be fluorescently labeled using viruses before assembly. We obtain AAVs from the SNI Gene Vector and Virus Core. AAV-DJ is generally our serotype of choice. However, we have successfully used other AAV serotypes 21 . We make lentiviruses in-house using standard protocols 47 . Briefly, transfect target plasmid and third/fourth-generation packaging plasmids in HEK 293T cells using Lipofectamine 2000. After collecting the supernatant, concentrate the lentivirus by incubation with a Lenti X concentrator (at 4°C for 30 min to overnight) followed by centrifugation (1,500g for 45 min at 4°C). 2 For labeling spheroids, add the virus to a 1.5-ml microcentrifuge tube containing one to three spheroids in 250 μl of NM (Reagent setup). Agitate the tube gently and incubate overnight in an incubator at 37°C, 5% CO 2 . c CRITICAL STEP The optimal titer for each virus must be empirically determined. 
Reagent setup
Reconstitution and storage of growth factor and chemical stock solutions Resuspend FGF2, EGF, BDNF, and NT3 growth factors in sterile 0.1% BSA and DPBS to the desired stock concentration. Stock solution concentrations are as follows: FGF2 stock solution, 20 μg/ml; use at 10 ng/ml for hPSCs (1:2,000) and 20 ng/ml for neural differentiation (1:1,000); EGF, BDNF and NT3 stock solutions, 20 μg/ml; use at 20 ng/ml (1:1,000). Resuspend 25 mg of DM in 12.52 ml of sterile dimethyl sulfoxide (DMSO) to obtain a 5 mM stock solution; use at a final concentration of 5 μM (1:1,000). Resuspend 10 mg of SB in 2.60 ml of 100% (vol/vol) ethanol to obtain a 10 mM stock solution; use at a final concentration of 10 μM (1:1,000). Resuspend 10 mg of IWP-2 in 4.29 ml of sterile DMSO to obtain a 5 mM stock solution; use at a final concentration of 5 μM (1:1,000). Resuspend 5 mg of SAG in 94.96 ml of sterile DMSO to obtain a 100 μM stock solution; use at a final concentration of 100 nM (1:1,000). Resuspend 5 mg of AlloP in 156.99 ml of sterile DMSO to obtain a 100 μM stock solution; use at a final concentration of 100 nM (1:1,000). Resuspend 50 mg of RA in 166.42 ml of sterile DMSO to obtain a 1 mM stock solution; further dilute the stock solution to obtain a 100 μM solution; use at a final concentration of 100 nM (1:1,000). Prepare aliquots of stock solutions and store at -80°C for up to 1 year. Once thawed, stocks can be kept at 4°C for up to 2 weeks.
General media guidance
Various media are required; compositions are as indicated below for each specific medium. When ready for use, add aliquots of required media to 50-ml sterile tubes and prewarm in a water bath at 37°C for <20 min. Avoid cycles of refrigeration and warming. c CRITICAL Add growth factors and small molecules immediately before use and only after prewarming aliquoted media.
MEF medium (for use in Steps 1 and 2). Prepare the medium as detailed in the table below. This medium can be stored for 1-2 weeks at 4°C. 
Dispase solution
Reconstitute dispase in hPSC medium (without growth factors) to a stock concentration of 1.75 mg/ml. Prepare aliquots of the stock solution and store at -20°C for up to 1 year. For hPSC passaging, thaw the dispase and dilute in hPSC medium to a concentration of 0.875 mg/ml. For lifting hPSC colonies for sphere formation, dilute the stock solution to 0.35 mg/ml in hPSC medium and warm in a water bath at 37°C for no more than 10 min. The working dispase solution can be kept at 4°C for up to 1 week.
Low-Ovo solution (10×; required only for single-cell dissociation) Add 3 g of BSA to 150 ml of DPBS and mix well. Add 3 g of trypsin inhibitor and mix to dissolve. Adjust the pH to 7.4; this requires the addition of~1 ml of 1 N NaOH. When completely dissolved, bring to a final volume of 200 ml with DPBS and filter through a 0.22-µm filter. Prepare 1.0-ml aliquots and store at -20˚C for up to 6 months.
High-Ovo solution (10×; required only for single-cell dissociation) Add 6 g of BSA to 150 ml of DPBS. Add 6 g of trypsin inhibitor and mix to dissolve. Adjust the pH to 7.4; this requires the addition of at least 1.5 ml of 1 N NaOH. If necessary, add NaOH until the solution is no longer too acidic. Bring to a final volume of 200 ml with DPBS. When completely dissolved, filter through a 0.22-µm filter. Prepare 1.0-ml aliquots and store at -20˚C for up to 6 months.
Paraformaldehyde
Prepare 4% (vol/vol) paraformaldehyde (PFA) by mixing 10 ml of 16% (vol/vol) PFA with 30 ml of deionized (DI) water, and store at 4°C for up to 1 week. ! CAUTION PFA must be handled in a safety cabinet and should be disposed of according to institutional guidelines.
Embedding solution
Prepare a 30% (wt/vol) sucrose solution by mixing 30 g of sucrose with DPBS to a final volume of 100 ml. Store the 30% (wt/vol) sucrose solution at 4°C for up to 2 weeks. Add 5 ml of OCT to 5 ml of 30% (wt/vol) sucrose to make a 1:1 embedding solution. Shake the solution vigorously until the OCT and sucrose have mixed together. Leave the mixed solution overnight at 4°C to allow bubbles formed during the mixing process to disappear.
Blocking solution for immunostaining
Prepare a blocking solution for immunostaining by mixing 10% (vol/vol) normal donkey serum with 0.3% (vol/vol) Triton X-100 in DPBS. Keep this solution at 4°C for up to 1 week.
Equipment setup
CO 2 tank
The 5% CO 2 tank setup should have plastic hosing leading to the culture hood and can include multiple three-way stops to split the hosing into multiple lines. To bubble CO 2 through solutions, attach a syringe filter to the end of the hosing, and then attach the broken end of a 2-ml pipette and place the tip into the liquid. During dissociation, place a syringe filter on the end of the plastic tubing and set the filter tip into a small hole cut into the lid of the Petri dish (without contacting the solution) so that CO 2 can be blown over the digesting solution. If this setup is not available, solutions can also be equilibrated in the incubator.
Procedure
MEF feeder seeding and initiation of hPSC cultures • Timing 2 h
1 Coat 10-cm cell culture dishes with 0.1% gelatin for at least 1 h at room temperature (RT) (~24°C). 2 Thaw one vial of MEFs (containing~5 × 10 6 cells) by placing it in a water bath at 37°C until it is 80% thawed (and for no longer than 2 min). Briefly spin the cells (at 200g for 4 min at RT) and plate at a density of 1-2 × 10 6 cells per 10-cm plate. 3 The next day, assess feeder quality before use; this will determine the quality of the hPSCs. Once the MEFs are ready for plating hPSCs (after~2 h), wash the culture plates at least once with fresh DPBS.
Passaging hPSCs on the MEF feeder layer • Timing 4-7 d
4 Remove hPSC medium from the refrigerator, aliquot the required amount into a centrifuge tube (~12 ml per 10-cm plate), wrap the container's cap with Parafilm to prevent contamination when putting it into the water bath, and warm in a water bath for up to 20 min. 5 Remove the hPSC plate from the incubator and look at it under a microscope. While under the microscope, mark the differentiated areas on the bottom of the plate, using a marker. Differentiated colonies may appear to have a hole or a pit in the center of the colony or a border of differentiated cells (Fig. 3a) . 6 After wiping with a paper towel sprayed with 70% (vol/vol) ethyl alcohol, transfer the plates to the cell culture hood. Then use a pipette tip to carefully remove demarcated differentiated colonies from the plate. 7 Aspirate the medium and add 5 ml of dispase (0.875 mg/ml in hPSC medium) to each culture plate, and place in the cell culture incubator for 7 min or until hPSC colonies have lifted. 8 Transfer the suspended cells from a single plate to a 50-ml centrifuge tube. Use 5 ml of hPSC medium with 10 ng/ml FGF2 and 10 µM Y-27632 to wash each 10-cm plate. Perform this step three times, adding the medium to the appropriate 50-ml centrifuge tube after each wash. 9 Gently swirl the 50-ml centrifuge tubes to suspend the harvested cells in 20 ml of hPSC medium. 10 Transfer the hPSC medium and suspended cells to a freshly prepared feeder plate (from Step 3).
11 Gently swirl the plate and slide the plate in a back-and-forth motion on the shelf of the incubator to evenly disperse the cells. 12 Incubate the cells in the cell culture incubator. Leave the cells undisturbed for the first day after passaging, and replace the medium every day thereafter for 5-7 d. To replace the medium, warm aliquoted fresh hPSC medium in a water bath for up to 10 min at 37°C, aspirate old medium from the plates, and add 12 ml of fresh medium per 10-cm culture plate. c CRITICAL STEP Replace hPSC culture medium at approximately the same time each day. 13 Monitor the hPSC colonies to determine when they are ready for spheroid formation. This will usually be~6-7 d from the last passage (depending on the hPSC line); colonies should measurẽ 1.5 mm in diameter. See Fig. 3a for examples of hPSC colonies of appropriate, and inappropriate, morphology. When cultures are ready, proceed to the next step. Alternatively, continue to passage hPSCs every 5-7 d (depending on the growth rate of each line) by repeating Steps 1-12; however, bear in mind that, ideally, hPSCs should not be kept beyond passage 40. c CRITICAL STEP It is essential for the colonies to be large in order to generate spheroids (i.e., just before the time at which colonies would be passaged, or 1-2 d later). If the colonies are too small, allow more time for growth before subsequent steps. Avoid using hPSC colonies that touch each other because they will detach as large clusters together with the MEF layer. Avoid hPSC colonies that have grown too large and that are differentiating in the center.
Suspending hPSC colonies to form spheroids • Timing 2-3 h
14 Remove the hPSC media from the culture plates. Detach hPSC colonies by incubating them with 0.35 mg/ml dispase (dissolved in hPSC medium; 5 ml per plate) for 30-45 min at 37°C, 5% CO 2 . Check the status of the detachment after 20 min and then every 5 min thereafter. Different lines will require different durations of dispase treatment. Plates can be gently moved (back and forth) at the end of the incubation period to facilitate the detachment of curled hPSC colonies from the feeders. Almost all feeders should remain attached to the 10-cm plate, whereas the hPSC colonies should come off. Intact colonies should curl up and lift off the plate (Fig. 3b) . 15 Gently transfer the floating colonies with a pre-wet 25-ml pipette to a 50-ml Falcon tube. Once the colonies settle at the bottom of the tube, aspirate the media and gently wash the colonies two times with 20 ml of warm hPSC medium (without growth factors). c CRITICAL STEP Do not centrifuge. Let the colonies settle at the bottom of the Falcon tube. ? TROUBLESHOOTING 16 Gently resuspend 30-50 suspended colonies in 12 ml of neural induction medium (the medium should also contain 5 µM DM, 10 µM SB, and 10 µM Y-27632) and transfer to a 10-cm ultra-lowattachment plate. Denote this day as day 0. Place the plate in the incubator at 37°C, 5% CO 2 for 48 h. Keep the spheroids in the incubator on day 1 without any medium change to allow the spheroids a day to recover. ! CAUTION It is important to distribute the spheroids evenly once the plate is placed in the incubator to avoid clustering and fusion of colonies at the center of the plate. Use NM supplemented with 20 ng/ml FGF2 and 20 ng/ml EGF. In addition, include 5 µm IWP-2 in the medium if you are generating hSSs. Change the medium daily on days 6-11. At day 6, neural spheroids should be~0.3-0.5 mm in diameter (Fig. 3c) . The medium can be changed as described in Step 17 or by gently tilting the plate (allowing the spheroids to settle) and removing the remaining medium. 22 From day 12 onward, the medium requirements for the generation of hCSs and hSSs deviate further. To generate hCSs, follow option A (see Fig. 2c for a detailed protocol timeline).
To generate hSSs, follow option B (see Fig. 2c for a detailed protocol timeline). To generate hSSs with more activity visible by calcium imaging 19 (hSS-ISRAs), follow option C. After neural spheroids grow larger (>2-3 mm in diameter), no more than 30 spheroids should be maintained per 10-cm plate. c CRITICAL STEP Neural spheroids tend to fuse to each other as they get larger (Fig. 3d) . When changing the medium, be sure to separate them by either pipetting up and down gently with a 10-ml pipette or by using a P10 pipette tip to separate them when they are bigger. If spheroids fuse during later time points (after~day 50), it may greatly compromise the outcome. (Fig. 2c) . On day 24, replace medium with NM without additional growth factors. ! CAUTION RA is air-and light-sensitive. Minimize light exposure. (iii) From days 25 to 43, replace FGF2 and EGF with 20 ng/ml BDNF and 20 ng/ml NT3.
Perform medium changes with 14-15 ml of supplemented NM per 10-cm plate every 2-3 d.
Maintenance and long-term culture • Timing indefinite
23 From day 43 onward, perform media changes with 17-18 ml of NM without growth factors every 4 d. Using careful sterile technique, spheroids can be maintained for many months in culture, if desired (Fig. 3d) . Carry out any additional procedures at time points determined by your experiment. Examples of additional procedures that can be carried out on the spheroids include the generation of forebrain assembloids (option A), dissociation into a single-cell suspension in preparation for further assays (option B), cryosectioning and immunolabeling (option C), calcium imaging (option D), and optical clearing by iDISCO (option E). Bear in mind that if you wish to assemble forebrain spheroids (option A), this procedure is most successful if the combined size of the assembled spheroids is <6 mm (between days 60 and 90 of culture). ? TROUBLESHOOTING (A) Generation of forebrain assembloids using hCSs and hSSs • Timing 3-7 d (i) For assembly of forebrain spheroids, transfer one hCS and one hSS to a 1.5-ml microcentrifuge tube that is resting in a standard microtube rack (Fig. 4f) . Denote the day of assembly as day 0. The size of the spheroids to be assembled should not exceed 3 mm, as they are challenging to fuse once they are too large. c CRITICAL STEP Once in the tube, make sure that there are no bubbles underneath the spheroids and that they rest next to each other in contact at the bottom of the tube and are not stacked up vertically.
(ii) Incubate the spheroids for at least 3 d in 1 ml of NM, completely replacing the medium on day 2. ! CAUTION Because the assembly interface is fragile at this stage, perform the medium change in the tube very carefully. ? TROUBLESHOOTING (iii) Check that fusion is complete. Fusion is considered complete when the two spheroids are inseparable with gentle shaking of the Eppendorf tube (Fig. 4g ). After fusion, use a P1000 pipette with the tip cut off for a larger bore opening to transfer the assembled hCS-hSSs back to the ultra-low-attachment 10-cm plates. If fusion is carried out between days 60 and 90, when this process is most efficient, hCS-hSS assembly is usually complete after 3- (i) At the time point of choice, transfer the spheroids to a 1.5-ml microcentrifuge tube, using a cut P1000 tip. Gently remove the medium and briefly wash with 1 ml of DPBS. Remove the DPBS and add 500 μl of cold 4% (vol/vol) PFA. Leave the spheres to fix for at least 30 min at 4°C. The optimal fixation time varies depending on the antibody being used, and the age and size of the spheres. We thus recommend fixation trials be undertaken to optimize the optimal fixation required for specific antibody stainings; e.g., for membrane antigens, we have found that fixation for shorter periods of time (~2 h) is optimal, whereas for nuclear antigens, optimal results are seen after a longer fixation (up to overnight). c CRITICAL STEP Use the same fixation and embedding protocol when quantifying across hCSs or hSSs derived from multiple hPSC lines and differentiations. Variation in fixation and the sample-processing protocol can lead to variability in antibody staining.
(ii) After fixation, gently remove PFA and perform three 15-min washes with DPBS at RT.
(iii) Add 1 ml of 30% (wt/vol) sucrose to facilitate cryoprotection. Leave the spheres in this solution at 4°C until they sink (~24-48 h). During this time, prepare the embedding solution (1:1, OCT/30% (wt/vol) sucrose; see the 'Reagent setup' section). (iv) To embed spheres, use square disposable molds that have been filled with embedding solution. c CRITICAL STEP To avoid creating bubbles while filling the mold, use a P1000 pipette, the tip of which has been slightly cut, to widen the opening. (v) Place the spheres into a mold using a P1000 cut pipette tip. Place four to ten spheroids into the mold, always making sure to mark their locations. If the spheres move while embedding, use a P20 tip to gently move them around the embedding solution. c CRITICAL STEP Avoid carrying excess 30% (wt/vol) sucrose when transferring the spheres. (vi) Place the mold on ice for 20 min and allow the spheres to sink to the bottom. (vii) Snap-freeze the spheres by placing the mold directly on dry ice. Once completely frozen, store the molds at −80°C. j PAUSE POINT Frozen molds can be stored indefinitely at -80°C until ready to cryosection. (viii) When ready for sectioning, remove the mold from the -80°C freezer and allow it to increase in temperature to -20°C by placing it in the cryostat chamber for~30 min before sectioning. (ix) Remove the block from the mold, use OCT to paste it onto a specimen stage, and section using standard techniques. Use a brush to prevent crumbling of the sections. We recommend that hCSs or hSSs be cryosectioned at a 10-to 15-μm thickness. Thicker sections are difficult to quantify because of the overlapping nuclei and high density of cells, especially in proliferative areas. However, if using a confocal microscope, thicker sections may be adequate. Let the ink dry and wash the slide with DPBS again to remove excess OCT. From this step onward, add all solutions within the circle. (xiv) Block for 1 h at RT with 10% NDS, 0.3% (vol/vol) Triton X-100, and DPBS. Note that the optimal concentration of NDS and Triton X-100 may vary according to the antigen of interest. c CRITICAL STEP Perform immunostaining steps in a humidified chamber to prevent sections from drying out. (xv) Add primary antibodies diluted in blocking solution at 4°C overnight. Some examples of antibodies and concentrations that we have used successfully are listed in Table 1 . c CRITICAL STEP Some antibodies might need longer incubation periods; therefore, further optimization may be required. See Fig. 4 for representative immunostainings of hCSs and hSSs with dorsal-and ventral-specific domain markers. c CRITICAL STEP Ideally, cryosections for quantification should be sampled throughout the thickness of the spheroid. Avoid quantification of cryo-sections that are not at least c CRITICAL STEP Make sure the chamber is completely sealed to the cover glass to avoid any benzyl ether leaking onto the microscope. We recommend visiting https://idisco.info/ for additional troubleshooting tips. (F) Live imaging of cell migration and calcium dynamics • Timing 2-24 h (i) Transfer a fused hCS-hSS to a well of a 96-well plate (glass-bottom plate) in 200 μl of neural medium. Owing to the limited amount of medium that can be included in a 96-well plate, avoid putting more than one brain assembloid into a well. (ii) Place a 96-well plate into an inverted microscope with a motorized stage under environmentally controlled conditions (37°C, 5% CO 2 ). (iii) Maintain the assembled spheroids in an environmentally controlled chamber for 30-60 min before imaging to let them acclimatize and settle. Movement in the room should be kept to a minimum. (iv) Set up the imaging positions so that up to~8 fields with z stacks (corresponding to eight assembled hCS-hSSs) can be imaged in a sequential manner, with each position or frame being imaged at a rate of 15-20 min per frame. Our z stacks normally span a depth of 50-150 μm and have a step size of 1.5-2.5 μm. We have found that hCS-hSSs can be imaged for up to~18 h, after which time imaging must be paused, so the medium should be carefully changed before continuing imaging. On our live-imaging system (Leica SP8 confocal microscope), we use <10% laser intensity per laser line with the 10× dry objective to avoid photobleaching and phototoxicity when imaging four to eight fields at a time. The laser power density should be empirically determined in other imaging systems. (v) If spheroids drift and this impacts image analysis, correct the images for drift computationally. We have found that the image registration plug-ins from ImageJ (e.g., linear stack alignment with SIFT) are generally sufficient to correct for minor-to-moderate drift. However, we discard sessions with major drift due to handling. Occasional drifting of spheroids may occur, as they are not embedded during imaging sessions.
Troubleshooting
Troubleshooting advice can be found in Table 2 . Examples of hCS or hSS experiments using calcium imaging, live imaging, and iDISCO can be found in Figure 4 of Pașca et al. 17 , Figures 2 and 3 of Birey et al. 19 , and Figure 2 and Extended Figure 10 of Birey et al. 19 , respectively.
